schizonepeta

Condiciones de salud que schizonepeta puede ayudar a apoyar.

• HipocondríaCientífico

  Wang et al. (Food Chem Toxicol 2012) confirmed Schizonepeta aqueous extract has significant radical scavenging, reducing activity, and liposome protection activity in vitro, identifying polyphenols (hesperidin, luteolin, diosmetin) as active components. Multiple studies confirm antioxidant enzyme induction. Evidence is entirely preclinical.

• EccemaCientífico

  Schizonepeta's anti-inflammatory mechanisms (NF-κB, MAPK, COX-2, TNF-α inhibition) are directly relevant to arthritis. The BMC study (2016) showed EEST protects against LPS-induced bone loss in a mouse model, with inhibition of osteoclastogenesis relevant to inflammatory arthritis. No human clinical trials for arthritis exist.

• Manchas de la edadCientífico

  Preclinical data from the 2016 BMC study show EEST protects against LPS-induced bone loss in mice by inhibiting osteoclastogenesis, with micro-CT confirmation of preserved bone structure. This directly supports a role in maintaining bone density. Evidence is animal-model only with no human data.

• ApendicitisCientífico

  Multiple preclinical studies confirm Schizonepeta suppresses key inflammatory mediators (NF-κB, MAPK, COX-2, TNF-α, IL-1β, IL-6) across cell and animal models. A 2025 systematic review of 13 preclinical studies confirmed anti-inflammatory mechanisms via multiple pathways. Evidence is preclinical; no human RCTs for chronic inflammation as a standalone endpoint exist.

• Vista (deficiente)Científico

  Schizonepeta is a principal herb in TCM formulas for allergic and atopic dermatitis, with clinical trial data and multiple animal studies. Controlled human trials of Xiao Feng San (which contains Schizonepeta) for atopic dermatitis, plus direct animal model evidence, support its anti-dermatitic activity.

• Parálisis de BellCientífico

  Schizonepeta appears in TCM formulas (particularly Xiao Feng San) evaluated in controlled trials for atopic eczema/dermatitis. Sheehan et al. published controlled trials in the Lancet (1992) and British Journal of Dermatology (1992) showing benefit for atopic eczema using a formula containing Schizonepeta. Animal and in vitro studies confirm anti-atopic-dermatitis mechanisms including suppression of IgE, TNF-α, and TRPV1.

• Deficiencia de CalcioCientífico

  Preclinical studies show Schizonepeta suppresses mast cell degranulation and histamine-related signaling, including in IgE-stimulated models. The 2025 systematic review confirmed histamine suppression among its documented effects. Evidence is in vitro/preclinical with no human histamine intolerance trials.

• Infección (bacteriana)Científico

  The BMC 2016 study (PMC4994400) directly concluded that EEST is a potential agent for treating osteoclast-related bone diseases such as osteoporosis, based on RANKL-induced osteoclastogenesis inhibition in vitro and LPS-induced bone erosion protection in vivo. Evidence is preclinical only.

• HalitosisCientífico

  The volatile oil of Schizonepeta tenuifolia was specifically studied and demonstrated anti-inflammatory effects in a carrageenan-induced rat pleurisy model (Shan et al., J Ethnopharmacol 2016). This is the most direct preclinical evidence linking the herb to pleural inflammation. No human clinical data exists.

• Dolor de cabeza (tensión)Científico

  The 2016 BMC study (PMC4994400) explicitly lists rheumatoid arthritis alongside osteoporosis as a target for EEST, given its osteoclast-inhibiting and anti-inflammatory properties. Preclinical data are the sole evidence; no human RA trials have been published.

• Sarpullido por pañalCientífico

  Multiple preclinical studies demonstrate Schizonepeta extract has direct antiviral activity against enterovirus 71 and norovirus, suppresses viral replication, and induces antiviral interferons. In vivo mouse data show improved survival in EV71-infected animals. No human clinical antiviral trials exist.

• DifteriaCientífico

  Preclinical studies have demonstrated that Schizonepeta extract promotes wound healing. The 2025 systematic review of 13 preclinical studies specifically lists wound healing promotion as one of Schizonepeta's confirmed pharmacological effects. Evidence is entirely preclinical with no human wound healing trials.

• Dolor AbdominalTradicional

  TCM traditions use Schizonepeta for early-stage skin infections including boils and abscesses, especially during the initial inflammatory phase with fever. It is considered the most important herb for skin infections in some TCM texts. Evidence is entirely traditional with no modern clinical studies.

• AbscesosTradicional

  Schizonepeta is used in TCM for skin infections and inflammatory skin lesions including boils and surface abscesses, under the category of wind-heat skin conditions. Its antibacterial and anti-inflammatory properties are documented in preclinical research. No clinical evidence specifically for acne exists.

• Abuso y TraumaTradicional

  Schizonepeta's TCM indications include respiratory allergic patterns with runny nose, sneezing, and itchy eyes. Its anti-allergic and immunomodulatory properties have been demonstrated preclinically via mast cell inhibition. No human clinical trials for respiratory allergies specifically have been published.

• ArritmiaTradicional

  Schizonepeta (Jing Jie) has been used in TCM for over 2,000 years as a primary herb for early-stage colds and flu. It is prescribed to release the exterior, induce mild perspiration, and relieve chills, fever, sore throat, and headache. It appears in classical formulas such as Jing Fang Bai Du San. No rigorous human RCTs isolating Schizonepeta alone for cold/flu exist.

• Sangrado (interno)Tradicional

  TCM texts spanning 2,000 years document Schizonepeta as an antipyretic herb used to lower fever in wind-cold and wind-heat conditions. Preclinical pharmacology confirms volatile-oil constituents have antipyretic properties in animal models, but human clinical trials isolating this effect are absent.

• Huesos RotosTradicional

  Schizonepeta is traditionally prescribed in TCM for headaches associated with external wind invasion, particularly those accompanying colds and fevers. Classical texts and multiple TCM formularies list it as a key herb for this indication. No independent human clinical trials confirm this use.

• Quemaduras y EscaldadurasTradicional

  Charred Schizonepeta has been used in TCM for heavy menstrual bleeding (menorrhagia/metrorrhagia) for centuries. The Chinese Pharmacopoeia records this use. Laboratory evidence confirms hemostatic mechanisms. WebMD and RxList list this as a traditional use. No human clinical trials isolating Schizonepeta for menorrhagia have been published.

• GiardiaTradicional

  Schizonepeta is listed in TCM references for early-stage mastitis, used alongside other herbs to expel wind-heat toxins and resolve surface-level breast inflammation. Evidence is entirely from TCM traditional documentation with no preclinical or clinical studies targeting mastitis specifically.

• Concentración (deficiente)Tradicional

  Charred (carbonized) Schizonepeta is a classical TCM hemostatic agent used for nosebleeds. The Qing Dynasty text Bencao Beiyao specifically documents this use. Laboratory studies confirm the carbonized form shortens clotting time and has hemostatic mechanisms, though no human clinical trials exist.

• Dolor de cabeza (en racimos)Tradicional

  Schizonepeta has been used in TCM for psoriasis under the paradigm of wind-heat skin conditions. Preclinical studies show immunomodulatory effects on T-cell cytokines (IFN-γ, IL-4) relevant to psoriatic pathology. No standalone controlled clinical trials for psoriasis have been published.

• CallosTradicional

  Schizonepeta is a foundational TCM herb for skin rashes and hives (urticaria), used to expel wind and vent rashes to the surface. It appears in classical formulas such as Xiao Feng San for wind-heat skin eruptions. Preclinical mast-cell studies provide mechanistic support, but no standalone human clinical trials exist.

• Tos (seca)Tradicional

  Schizonepeta is used in TCM for allergic conditions including seasonal allergic symptoms, attributed to its wind-expelling and anti-allergic properties. In vitro studies demonstrate inhibition of mast cell degranulation and pro-inflammatory cytokines relevant to allergic cascades. Human clinical evidence for seasonal allergy specifically is absent.

• Tos (espasmódica)Tradicional

  TCM sources list Schizonepeta for nasal congestion, sinusitis, and related wind-invasion symptoms. It is included in classical formulas for stuffy and runny nose. Preclinical anti-inflammatory effects provide mechanistic plausibility. No isolated human clinical trials have been conducted for this indication.

• Enfermedad de CushingTradicional

  TCM tradition documents Schizonepeta for sore throat, particularly during early-stage external invasions (wind-cold or wind-heat). It is included in classical formulas addressing throat pain alongside fever and chills. No controlled human trials specifically for sore throat have been published.

• DefensividadTradicional

  Schizonepeta has been used for over 2,000 years in TCM for upper respiratory conditions including colds, sore throat, nasal congestion, and early respiratory infections. It is categorized as an exterior-releasing herb that supports the body's defense against respiratory pathogens. Evidence is primarily traditional and preclinical.

Sistemas corporales que schizonepeta puede ayudar a apoyar.

• No hay sistemas corporales disponibles.